OncoMatch/Clinical Trials/NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Is NCT05875168 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies DS-3939a for advanced solid tumor.
Treatment: DS-3939a — This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: muc1-targeted therapy
Lab requirements
Cardiac function
left ventricular ejection fraction ≥50% by either an echocardiogram or multigated acquisition within 28 days of enrollment
Has a left ventricular ejection fraction ≥50% by either an echocardiogram or multigated acquisition within 28 days of enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- Oregon Health & Science University · Portland, Oregon
- Rhode Island Hospital · Providence, Rhode Island
- University of Texas M.D. Anderson Cancer Center · Houston, Texas
- Huntsman Cancer Institute, University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05875168 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior muc1-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify